Navigation Links
Breast Cancer Vaccine Being Developed by Generex Subsidiary Antigen Express to be Featured on Bloomberg Television Today
Date:12/19/2011

>

This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plan," "believes," "will," "achieve," "anticipate," "would," "should," "subject to" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials or ultimate regulatory approval cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials or when it will obtain ultimate regulatory approval by a particular regulatory agency. Generex claims the pr
'/>"/>

SOURCE Generex Biotechnology Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Pipeline for Breast Cancer Therapies is Focus of New MedPredict Report
2. alli(TM) Partners with Breast Cancer Network of Strength(TM) to Support Women Challenged by Breast Cancer, Weight Loss or Both
3. Monogram and Dana-Farber Cancer Institute Initiate Evaluation of HERmark(TM) Breast Cancer Assay in Metastatic Breast Cancer
4. Video: Women Unsatisfied With Body and Breasts, Less Likely to Comply With Screenings, Including Mammography
5. 23andMe Announces Breast Cancer Initiative
6. Amoena Helps Women Re-shape Their Lives After Breast Cancer Surgery
7. Peregrine Pharmaceuticals Reports Progress in Its Phase II Trial of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer
8. Solos Endoscopy, Inc. Applauds American College of Surgeons Review of Advanced Breast Cancer Detection at 94th Annual Clinical Congress
9. Brain Fitness Program Offers Hope for Breast Cancer Survivors Suffering From Chemobrain
10. James L. Wittliff, Ph.D., FACB, to Present Predicting Breast Cancer Outcome with Gene Expression Signatures on the Ziplex(R) System at the Association for Molecular Pathology Conference, October 30
11. Diagenic Partners With DNAVision to Offer First Breast Cancer and Alzheimers Gene-Expression Blood Tests
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... , July 23, 2014  Sofinnova Ventures, a ... announced the closing of Sofinnova Venture Partners IX, L.P. ... excess of the initial fund target of $425 million. ... successful biotechnology companies. Consistent with recent funds, SVP IX ... stage clinical programs, along with select investments in earlier ...
(Date:7/23/2014)... 23, 2014 a2z Inc. announces that ... App, AACC Pathfinder, in its 2014 Annual Meeting ... meeting is planned for July 29-31, 2014 in Chicago, ... be to connect with global leaders in clinical chemistry, ... other areas of breaking science in laboratory medicine. , ...
(Date:7/22/2014)... The Board of Directors of BD (Becton, Dickinson ... quarterly dividend of 54.5 cents per common share payable on ... 2014. The indicated annual dividend rate is $2.18 per share. ... leading medical technology company that partners with customers and stakeholders ... health needs. Our innovative solutions are focused on improving drug ...
(Date:7/22/2014)... in mechanical engineering at the University of Texas at ... the North Texas section of the American Society of ... members in 158 countries who develop engineering standards and ... community, benefiting the world. , ASME recognized Baughn earlier ... honors banquet. Baughn retired as an engineering fellow in ...
Breaking Biology Technology:Sofinnova Raises $500 Million Biotech Venture Fund 2AACC Enhances Attendee Experience at Its 2014 Annual Meeting & Clinical Lab Expo with a2z-Powered ChirpE Photo Booth and Mobile App 2AACC Enhances Attendee Experience at Its 2014 Annual Meeting & Clinical Lab Expo with a2z-Powered ChirpE Photo Booth and Mobile App 3UT Dallas professor receives Engineer of the Year award 2
... a Madison-based company engaged in gene therapy and the study of ... new injection delivery method. , ,The company has been working to ... such as RNA for the study of gene function, and along ... developed a more rapid method of injection. , ,RNA interference ...
... Editor's note: This is the final in a three-part ... part of WTN Media's Boardroom Perspectives column, are written ... Candela Solutions, LLC . , ,According to the ... percent of frauds are detected by someone saying something ...
... my last article of the year, and I have talked less ... Year's resolution for this column is bring back more music (hopefully ... I simply have not gone to as many concerts this past ... to remedy!) , ,Looking over 2006, my focus has been more ...
Cached Biology Technology:Mirus Bio awarded patent on RNA delivery 2Mirus Bio awarded patent on RNA delivery 3I can tell you - you're my lawyer, right? 2I can tell you - you're my lawyer, right? 3I can tell you - you're my lawyer, right? 4I can tell you - you're my lawyer, right? 5I can tell you - you're my lawyer, right? 62006: A great biotech financing year, unless you were going public! 22006: A great biotech financing year, unless you were going public! 32006: A great biotech financing year, unless you were going public! 42006: A great biotech financing year, unless you were going public! 5
(Date:7/23/2014)... (PHILADELPHIA) The Worldwide Innovative Networking in personalized cancer ... Kimmel Cancer Center at Thomas Jefferson University ... the only member of this prestigious group in the ... the delivery of innovative personalized medicine to the patient ... patient advocacy. , "Our participation in the WIN consortium ...
(Date:7/23/2014)... clinical use of induced pluripotent stem cell (iPSC) ... hindered by the risk of dysregulated cell growth, ... use etoposide treatment to halt teratoma formation in ... acute myocardial infarction, is demonstrated in an article ... peer-reviewed journal from Mary Ann Liebert, Inc., publishers. ...
(Date:7/23/2014)... , July 23, 2014 ... its new report, GLOBAL MARKETS AND TECHNOLOGIES FOR ... technologies is expected to grow to nearly $154.4 billion ... (CAGR) of 10.1%. The image, flow, and level sensors ...      (Logo: http://photos.prnewswire.com/prnh/20140723/694805 ) , ...
Breaking Biology News(10 mins):New partnership brings more personalized cancer treatment to Philadelphia 2Global Market for Sensors to Reach Nearly $154.4 Billion in 2020; Image Sensors Moving at 11.7% 2Global Market for Sensors to Reach Nearly $154.4 Billion in 2020; Image Sensors Moving at 11.7% 3
... study was conducted by researchers from Scripps Research; the ... Taiwan University. It is being published today in the ... Chi-Huey Wong is currently the Ernest W. Hahn Chair ... and directs the Scripps Research lab heading the study. ...
... is your goal, you can't do better than to emulate ... and an unusual pitching stroke that allows the bug to ... is a marvel of engineering. , Z. Jane Wang, professor ... research on flying systems and fluid dynamics today (Feb. 19) ...
... mention the cleaning product industry, repeatedly warn of their ... is raising the intriguing idea that persistent bacterial and ... Robert W. and Vivian K. Cahill Professor in Cancer ... an essay in the Feb. 24 issue of the ...
Cached Biology News:Enzyme inhibitors block replication of SARS virus 2Scientist uses dragonflies to better understand flight 2Scientists look to the Bahamas as a model for coral reef conservation 2Scientists look to the Bahamas as a model for coral reef conservation 3
... The LCMS-2010EV is a fully flexible quadrupole ... conventional HPLC, high-speed HPLC, 1-D and 2-D ... scale separations. It incorporates a drying gas ... for high sensitivity, especially for low-to-medium polarity ...
Vapor phase risers are available in various heights to accomodate a variety of inventory solutions. Risers are used to creat a false bottom in which the tanks platform rests and Liquid nitrogen is s...
SP6 RNA Polymerase, 50 l, 20 U/l ,Cap Scribe Buffer, 100 l, 5x conc....
...
Biology Products: